Frankfurt
01.09.26 | 09:28
0,642 Euro
-0,31 % -0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | AlzeCure Pharma to Present at The Pareto Securities 17th Annual Healthcare Conference on September 2 | 406 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | AlzeCure Pharma AB: AlzeCure publishes its interim report for January - June 2026 | 121 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June 2026 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During... ► Artikel lesen | |
| 18.08. | AlzeCure Pharma: AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction with Lilly | 1.423 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 18, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 12.08. | AlzeCure Pharma: AlzeCure Receives a Total Upfront Payment of USD 12 million and Completes the Initial Transaction with QuantumCell | 473 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 12, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus... ► Artikel lesen | |
| 03.08. | AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell | 335 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / August 3, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered... ► Artikel lesen | |
| 02.07. | AlzeCure Pharma: Final Outcome of AlzeCure's Rights Issue | 582 | ACCESS Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES... ► Artikel lesen | |
| 01.07. | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 3 | Pharmaceutical Technology | ||
| 01.07. | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| 01.07. | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| 01.07. | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| 01.07. | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 630 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 29.06. | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 676 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 575 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 479 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 15.06. | Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 286 | GlobeNewswire | With effect from June 16, 2026, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including June 25, 2026.
... ► Artikel lesen | |
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 6 | Pharmaceutical Technology | ||
| 10.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.06.2026 | 333 | Xetra Newsboard | Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.06.2026 und ex Kapitalmassnahme am 11.06.2026 The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY... ► Artikel lesen | |
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | 8 | FierceBiotech | ||
| 09.06. | Lilly, AlzeCure ink Alzheimer's drug deal worth more than $1B | 11 | Seeking Alpha | ||
| 09.06. | 1-Milliarde-Deal: Alzheimer-Hammer: Lilly schickt Mini-Biotech um 553 % nach oben | 1.040 | wallstreetONLINE | © Foto: OpenAIEli Lilly setzt mit AlzeCure auf eine Alzheimer-Tablette - und lässt die Aktie des kleinen Biotechs um mehr als 550 Prozent explodieren.Eli Lilly hat mit AlzeCure Pharma einen Kooperations-... ► Artikel lesen |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 469,75 | +0,20 % | Vertex Pharmaceuticals Incorporated: Vertex to Participate in Upcoming September Investor Conferences | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.
Susie Lisa, Senior Vice President of Investor Relations... ► Artikel lesen | |
| VIATRIS | 14,404 | +1,38 % | Citizens reiterates Opus Genetics stock rating on Viatris partnership potential | ||
| ALTIMMUNE | 2,715 | +1,88 % | Altimmune, Inc: Altimmune Announces Second Quarter 2026 Financial Results and Business Update | Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,500 | 0,00 % | Frank Gerola's BMF Targets SELLAS Life Sciences $3 Billion Valuation: Biotech's 'Most Expensive Coin Flip' | ||
| OPKO HEALTH | 1,250 | -1,57 % | OPKO HEALTH, INC. - 10-Q/A, Quarterly Report | ||
| JAGUAR HEALTH | 0,798 | +0,88 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
28.08.2026 / 14:44 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,760 | -0,83 % | Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock | ||
| KIORA PHARMACEUTICALS | 2,520 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation | Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights... ► Artikel lesen | |
| LIPOCINE | 2,270 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 | SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 5,270 | +1,05 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) | WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory... ► Artikel lesen | |
| PHOTOCURE | 4,925 | 0,00 % | Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II | OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 19,950 | 0,00 % | Eurobio Scientific: First half of 2026, Continuation of the strategic transformation | FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 millionContinuation of the Group's strategy: Proprietary products: 37% of revenueInternational expansion:... ► Artikel lesen | |
| MEDICURE | 1,570 | 0,00 % | Medicure, Inc.: Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call | WINNIPEG, MB / ACCESS Newswire / August 14, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 48,710 | -0,67 % | Aus für die Chemie-Keule: Bayer-Partner MustGrow Biologics mit Fortschritten - hat sich Bioceres verhoben? | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Die Landwirtschaft steht vor einer Zäsur. Strenge Umweltauflagen verbannen chemische Pflanzenschutzmittel zunehmend von den Feldern.... ► Artikel lesen | |
| MERCK KGAA | 141,15 | +1,55 % | Milliardenmarkt Krebs: Moderna und Merck läuten die nächste Biotech-Ära ein | Ein Durchbruch in der Krebsforschung sorgt für Euphorie an der Börse. Moderna und Merck feiern einen Studienerfolg. Jetzt hoffen Anleger auf die nächste große Biotech-Rallye und neue Milliardenmärkte.... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,31 % bei einem Aktienkurs von 0,642 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.